Diagonal Therapeutics secures $125M in Series B funding to advance DIAG723, targeting rare diseases HHT and PAH, led by Sanofi Ventures.
Amount Raised
$125 Million
Round Type
Series B
CambridgeBiotechnologyHealth CareInvestors
Description
Diagonal Therapeutics has raised $125 million in a Series B financing round to advance its DIAG723 drug for hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension. The funding, led by Sanofi Ventures, will support the company's first-in-human trial. Diagonal aims to address critical gaps in treatment for these rare diseases. CEO Alex Lugovskoy highlighted the potential of DIAG723 in reversing disease pathology.
Quick answer
Diagonal Therapeutics raised $125 Million in a Series B round, dated January 8, 2026. Investors: James Henderson Investors and Sanofi Ventures. Diagonal Therapeutics is based in Cambridge, Massachusetts, United States.
- How much did Diagonal Therapeutics raise?
- Diagonal Therapeutics raised $125 Million in a Series B round on January 8, 2026.
- Who invested in Diagonal Therapeutics?
- James Henderson Investors and Sanofi Ventures are named as investors in this round.
- What does Diagonal Therapeutics do?
- Diagonal Therapeutics is a biotech company pioneering a new approach to discovering and developing agonist antibodies.
- Where is Diagonal Therapeutics based and how big is it?
- Diagonal Therapeutics is based in Cambridge, Massachusetts, United States. Fundz records about 28 employees.
- Who are the decision-makers at Diagonal Therapeutics?
- Fundz holds 1 contact at Diagonal Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology and Health Care around the same time
Companies in the same sectors as Diagonal Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- QSTEM raised $1.5M (Seed) on February 20, 2026.
- Altesa raised $75M (Series B) on February 19, 2026.
- Lario Therapeutics raised $2.4M (Grant) on February 19, 2026.
- Epetōme raised an undisclosed amount on February 19, 2026.
- Elumn8 Medical raised an undisclosed amount (Series C) on February 18, 2026.
- Faeth Therapeutics raised $200M (Post-IPO Equity) on February 18, 2026.
Who to call at Diagonal Therapeutics, and when
A new round usually means Diagonal Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Diagonal Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Diagonal Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Diagonal Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Diagonal Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansDiagonal Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.